ENTITY
FDA Delays Decision on Amgen’s Lumakras and Vectibix Combination for Metastatic Colorectal Cancer
FDA, Amgen, Lumakras, Vectibix, metastatic colorectal cancer, KRAS G12C mutation, sotorasib, panitumumab
FDA Approves Avadel’s Lumryz for Pediatric Narcolepsy Patients
Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)
FDA Approves Vyalev: A Breakthrough Continuous Infusion Therapy for Advanced Parkinson’s Disease
Vyalev, Parkinson’s disease, continuous infusion therapy, FDA approval, AbbVie, motor fluctuations, levodopa, carbidopa
Bavarian Nordic’s Mpox Vaccine Demonstrates Equivalent Efficacy in Teens and Adults: NIH Study
Mpox vaccine, Bavarian Nordic, MVA-BN vaccine, Teenagers, Adults, Antibody response, Safety, Efficacy, NIH study
Sanofi Invests €300M in Orano Med for Next-Generation Radioligand Therapies
Sanofi, Orano Med, Radioligand Therapies, Rare Cancers, AlphaMedix, Lead-212 (212Pb), Targeted Alpha Therapies
FDA Approves Novocure’s Optune Lua for Metastatic Non-Small Cell Lung Cancer Treatment
Optune Lua, FDA approval, metastatic non-small cell lung cancer, Tumor Treating Fields, Novocure, NSCLC treatment.
Eisai to Seek Reconsideration of TGA’s Initial Decision on Lecanemab for Alzheimer’s Disease in Australia
Lecanemab, Alzheimer’s disease, Therapeutic Goods Administration (TGA), Eisai, Biogen, reconsideration, Australia
Wave Life Sciences Sees Historic Stock Surge Following Breakthrough in RNA Editing Therapy
Wave Life Sciences, RNA editing, genetic condition, lung and liver complications, WVE-006, biotech, stock surge, clinical trial data
KdT Ventures Secures $100M Fourth Fund to Fuel Early-Stage Biotech Startups
KdT Ventures, $100M fund, early-stage startups, biotech, frontier science, life sciences investment
Enhancing GI Tolerability of GLP-1 Receptor Agonists: A Path to Improved Therapeutic Outcomes
GLP-1 receptor agonists, gastrointestinal tolerability, therapeutic strategies, diabetes management, obesity treatment